MAP17 overexpression is a common characteristic of carcinomas.
about
Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator.MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis.MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer.A genetic view of laryngeal cancer heterogeneityEfficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).p38α limits the contribution of MAP17 to cancer progression in breast tumors.Impaired in vitro erythropoiesis following deletion of the Scl (Tal1) +40 enhancer is largely compensated for in vivo despite a significant reduction in expressionHaCaT Keratinocytes and Primary Epidermal Keratinocytes Have Different Transcriptional Profiles of Cornified Envelope-Associated Genes to T Helper Cell Cytokines.MAP17, a ROS-dependent oncogene.Reduced expression of ELAVL4 in male meningioma patients.Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma.The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.Screening and identification of distant metastasis-related differentially expressed genes in human squamous cell lung carcinoma.Genome-wide screening and co-expression network analysis identify recurrence-specific biomarkers of esophageal squamous cell carcinoma.Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinomaMAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy
P2860
Q33470262-FE380FCE-080A-4F9D-82F5-CC563E952914Q34589895-E0C4E5DF-B5FF-4BF3-B43F-FA12E2A33328Q35092066-A3998CBB-EFF3-4B00-8FD4-419985621731Q35828640-76FC57A0-EBC0-4401-BEA3-000E2DFE0189Q36557595-E3387483-70F2-4066-870D-F67098349258Q36972817-EDF519F7-67CE-4671-A174-CC407C1E2045Q37687113-244ABD54-BA4A-48DE-849F-6C18A96CA22BQ39408183-B75C39CC-CA9D-4F03-B44F-2DF94A8E8857Q41447688-DB826C00-3AD6-418C-8DA1-08CAB96315A4Q42182741-165E7E5F-8B15-46F4-8065-26583F21900EQ42323237-88B63984-CC3F-4FA5-9940-FDE838FE4401Q45399334-5E0726FB-BD08-4E0A-B1B3-62EF98284486Q46112391-FF94B986-7A14-4CE5-B598-7946C224E557Q47122756-D114DDB8-9C7F-41B1-8DBE-A6C83C9522C2Q51541269-3DCA9CD9-D61C-4277-B3A4-EBEFE4C2FAEDQ54196068-9C90DA83-C010-40EC-B40A-DECC2B5B74C2Q55059319-09CE1ABB-B408-4A3D-B4EC-3837E3310EBAQ55227686-9D1927AA-D7CF-45B5-8590-016F87BBD5E6Q58770545-38DE7AB1-A85E-43D1-BA3E-82FB3E5B6326Q58779402-EAA3BD29-F8B9-4E8E-B897-8F16ACB8C291
P2860
MAP17 overexpression is a common characteristic of carcinomas.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
MAP17 overexpression is a common characteristic of carcinomas.
@ast
MAP17 overexpression is a common characteristic of carcinomas.
@en
MAP17 overexpression is a common characteristic of carcinomas.
@nl
type
label
MAP17 overexpression is a common characteristic of carcinomas.
@ast
MAP17 overexpression is a common characteristic of carcinomas.
@en
MAP17 overexpression is a common characteristic of carcinomas.
@nl
prefLabel
MAP17 overexpression is a common characteristic of carcinomas.
@ast
MAP17 overexpression is a common characteristic of carcinomas.
@en
MAP17 overexpression is a common characteristic of carcinomas.
@nl
P2093
P50
P356
P1433
P1476
MAP17 overexpression is a common characteristic of carcinomas.
@en
P2093
Jesus Fominaya
Maria V Guijarro
Matilde Lleonart
Soledad Alonso
P304
P356
10.1093/CARCIN/BGM083
P407
P50
P577
2007-04-09T00:00:00Z